IDEAYA Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 32.89 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.17B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Details
| Name | IDEAYA Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 145 |
| Founded | 2015 |
| Ipo Date | 2019-05-23 |
| Ceo | Yujiro Hata |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 10.00 |
| Isin | US45166A1025 |
| Cusip | 45166A102 |
| Cik | 1676725 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Yujiro S. Hata | Founder, President, Chief Executive Officer and Chairman |
| Dr. Joshua Bleharski M.B.A., Ph.D. | Chief Financial Officer |
| Andres Ruiz Briseno CPA | Chief Accounting Officer |
| Douglas B. Snyder | Chief Legal Officer |
| Dr. Michael A. White Ph.D. | President of Research and Development |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Francine Zelaya | Senior Vice President and Head of Human Resources |
| Mick O'Quigley | Senior Vice President of Medical Writing and Project Management |
| Daniel A. Simon | Chief Business Officer |
Contact
| Address | 5000 Shoreline Court, Suite 300, South San Francisco, California 94080, United States |
| Phone | 650 443 6209 |
| Website | https://www.ideayabio.com |